Valeant Pharmaceuticals PT Raised to $140.00 at JPMorgan Chase & Co. (VRX)
Investment analysts at JPMorgan Chase & Co. hoisted their price objective on shares of Valeant Pharmaceuticals (NYSE:VRX) from $125.00 to $140.00 in a note issued to investors on Wednesday, Analyst Ratings News reports. JPMorgan Chase & Co.’s price objective indicates a potential upside of 9.12% from the stock’s previous close.
Shares of Valeant Pharmaceuticals (NYSE:VRX) traded up 2.35% during mid-day trading on Wednesday, hitting $128.30. 3,025,998 shares of the company’s stock traded hands. Valeant Pharmaceuticals has a 52 week low of $62.80 and a 52 week high of $135.73. The stock has a 50-day moving average of $111.5 and a 200-day moving average of $103.4. The company’s market cap is $42.838 billion.
Valeant Pharmaceuticals (NYSE:VRX) last announced its earnings results on Thursday, October 31st. The company reported $1.51 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.40 by $0.11. The company had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $884.14 million. During the same quarter in the previous year, the company posted $1.15 earnings per share. The company’s revenue for the quarter was up 74.4% on a year-over-year basis. On average, analysts predict that Valeant Pharmaceuticals will post $6.13 earnings per share for the current fiscal year.
VRX has been the subject of a number of other recent research reports. Analysts at BMO Capital Markets raised their price target on shares of Valeant Pharmaceuticals from $132.00 to $146.00 in a research note to investors on Wednesday. Separately, analysts at Canaccord Genuity raised their price target on shares of Valeant Pharmaceuticals from $115.00 to $119.00 in a research note to investors on Tuesday, December 17th. Finally, analysts at UBS AG raised their price target on shares of Valeant Pharmaceuticals from $115.00 to $125.00 in a research note to investors on Tuesday, December 3rd. They now have a “buy” rating on the stock. Two research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $127.96.
Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.